Pre-apheresis T-cell fitness in chimeric antigen receptor T-cell therapy

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed outcomes in patients with relapsed or refractory hematologic malignancies, yet clinical responses remain heterogeneous. Increasing evidence suggests that part of this variability may already be reflected before manufacturing, at the level of the leukapheresis starting material. This review highlights pre-apheresis T-cell fitness as an important upstream biological framework linking patient background to the quality of the starting material, manufacturing performance, and clinical efficacy. Available data indicate that the most informative attributes of high-quality starting material are defined not by T-cell number alone but by the preservation of early-differentiated T-cell subsets, maintenance of functional reserve, resilience to exhaustion-associated dysfunction, and metabolic adaptability. We discuss how prior treatment exposures, including chemotherapy, radiotherapy, and selected targeted agents, can influence these properties according to exposure type, dose intensity, treatment phase, and timing relative to leukapheresis. We further examine how host-related conditions, including immunosenescence, chronic infection, nutritional and metabolic imbalance, and high tumor burden, may alter precursor availability, reshape differentiation architecture, and impair T-cell functional competence before collection. Collectively, these observations support a shift from a quantitative view of leukapheresis products toward a biologically informed assessment of T-cell quality. Defining a favorable pre-collection window and establishing standardized pre-apheresis assessment strategies may therefore facilitate biologically informed leukapheresis planning and future optimization of CAR-T manufacturing and clinical outcomes.

Authors

Institutions

Publication Details

Journal
Translational Oncology
Published
2026-11-14
DOI
https://doi.org/10.1016/j.tranon.2026.103115
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pre-apheresis T-cell fitness in chimeric antigen receptor T-cell therapy

Qing Li, Xiaojian Zhu, Yue Chun
Translational Oncology
CAR-T cell therapy research
article

Pre-apheresis T-cell fitness in chimeric antigen receptor T-cell therapy

Qing Li, Xiaojian Zhu, Yue Chun
article en

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed outcomes in patients with relapsed or refractory hematologic malignancies, yet clinical responses remain heterogeneous. Increasing evidence suggests that part of this variability may already be reflected before manufacturing, at the level of the leukapheresis starting material. This review highlights pre-apheresis T-cell fitness as an important upstream biological framework linking patient background to the quality of the starting material, manufacturing performance, and clinical efficacy. Available data indicate that the most informative attributes of high-quality starting material are defined not by T-cell number alone but by the preservation of early-differentiated T-cell subsets, maintenance of functional reserve, resilience to exhaustion-associated dysfunction, and metabolic adaptability. We discuss how prior treatment exposures, including chemotherapy, radiotherapy, and selected targeted agents, can influence these properties according to exposure type, dose intensity, treatment phase, and timing relative to leukapheresis. We further examine how host-related conditions, including immunosenescence, chronic infection, nutritional and metabolic imbalance, and high tumor burden, may alter precursor availability, reshape differentiation architecture, and impair T-cell functional competence before collection. Collectively, these observations support a shift from a quantitative view of leukapheresis products toward a biologically informed assessment of T-cell quality. Defining a favorable pre-collection window and establishing standardized pre-apheresis assessment strategies may therefore facilitate biologically informed leukapheresis planning and future optimization of CAR-T manufacturing and clinical outcomes.

Translational OncologyVol. 75
Wuhan No.1 Hospital (CN), Wuhan No.9 Hospital (CN), Tongji Hospital (CN), Huazhong University of Science and Technology (CN)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon